3SBio Inc.
Research 3SBio Inc. (1530.HK) on Bullrun: market cap HKD 35.84B, P/E 3.9, dividend yield 1.7%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker1530.HK
- ExchangeHK
- CountryChina
- SectorHealthcare
- IndustryBiotechnology
- CurrencyHKD
- Market capHKD 35.84B
- P/E3.9
- Dividend yield1.7%
- Financial periodFY2025
- RevenueCNY 17.70B
- Revenue growth94.3%
- Net incomeCNY 8.48B
- Free cash flowCNY 9.13B
- Gross margin92.4%
Valuation Snapshot
latest market cap is HKD 35.84B; P/E is 3.9; dividend yield is 1.7%.
Peer valuation comparison
Latest P/E is 3.91x versus a Healthcare sector median of 21.75x (82.0% below).
Latest dividend yield is 1.73% versus a Healthcare sector median of 2.4% (27.9% below).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | CNY 17.70B | CNY 8.48B | CNY 9.13B | 92.4% | 3.43 | CNY 15.50B | CNY 2.62B | CNY 27.21B |
| FY2024 | CNY 9.11B | CNY 2.09B | CNY 2.24B | 86.0% | 0.85 | CNY 2.02B | CNY 3.55B | CNY 15.44B |
| FY2023 | CNY 7.82B | CNY 1.55B | CNY 1.38B | 85.0% | 0.62 | CNY 2.69B | CNY 4.84B | CNY 14.03B |
| FY2022 | CNY 6.87B | CNY 1.92B | CNY 1.16B | 82.6% | 0.74 | CNY 2.15B | CNY 4.52B | CNY 12.93B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | HKD 35.84B | 3.9 | 1.7% | 0.25 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0.25 HKD, yield 1.7%.
| Year | Dividends/share |
|---|---|
| FY2025 | 0.25 CNY |
| FY2024 | 0.25 CNY |
| FY2023 | 0.1 CNY |
| FY2022 | 0.2 CNY |
About 3SBio Inc.
3SBio Inc., an investment holding company, engages in the development, production, marketing, and sale of biopharmaceutical products in the People's Republic of China, the United States, and internationally. The company offers TPIAO bio-pharmaceutical drug for the treatment of chemotherapy-induced thrombocytopenia, immune thrombocytopenia, pediatric ITP, and chronic liver disease-related thrombocytopenia.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is 3SBio Inc.'s market cap?
3SBio Inc.'s market capitalization is HKD 35.84B.
What is 3SBio Inc.'s P/E ratio?
3SBio Inc.'s price-to-earnings (P/E) ratio is 3.9.
Does 3SBio Inc. pay a dividend?
3SBio Inc. has a dividend yield of 1.7%.
What does 3SBio Inc. do?
3SBio Inc., an investment holding company, engages in the development, production, marketing, and sale of biopharmaceutical products in the People's Republic of China, the United States, and internationally. The company offers TPIAO bio-pharmaceutical drug for the treatment of chemotherapy-induced thrombocytopenia, immune thrombocytopenia, pediatric ITP, and chronic liver disease-related thrombocytopenia.